Large B-cell lymphoma (LBCL) predominantly affects older adults with generally suboptimal
outcomes even when treated with curative intent. 1 In the relapsed/refractory setting, the …

Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in
the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel and axicabtagene …

Introduction: Chimeric antigen receptor (CAR) T-cell therapy has shown durable responses
in 40-50% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). For …

Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …

Introduction Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising
treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and Drug …

Corticosteroids are commonly used for the management of severe toxicities associated with
chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their …

Treatment with high‐dose chemotherapy followed by autologous stem cell transplantation
(ASCT) is considered standard of care (SOC) second‐line treatment for relapsed or …

Purpose Chimeric antigen receptor T-cell (CAR T) therapy is capable of eliciting durable
responses in patients with relapsed/refractory (R/R) lymphomas. However, most treated …

The emergence of chimeric antigen receptor (CAR) T-cell therapy has changed the
treatment landscape for diffuse large B-cell lymphoma (DLBCL); however, real-world …

PURPOSE Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved
for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; …